TASP1
| TASP1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | TASP1, C20orf13, dJ585I14.2, taspase 1, SULEHS | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 608270; MGI: 1923062; GeneCards: TASP1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Threonine aspartase 1 is an enzyme that in humans is encoded by the TASP1 gene.[5][6]
Function
[edit]This gene encodes an endopeptidase that cleaves specific substrates following aspartate residues. The encoded protein undergoes posttranslational autoproteolytic processing to generate alpha and beta subunits, which reassemble into the active alpha2-beta2 heterotetramer. It is required to cleave MLL, a protein required for the maintenance of HOX gene expression, and TFIIA, a basal transcription factor. Cleavage of TFIIA has been found to drive spermatogenesis.[7]
Alternatively spliced transcript variants have been described, but their biological validity has not been determined.[6]
Clinical significance
[edit]Taspase1 is overexpressed in primary human cancers and functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Therefore, Taspase1 may serve as a novel anti-cancer therapeutic target.[8] A mutation of the TASP1 gene causes Suleiman-El-Hattab syndrome, a genetic disorder recently described in 2018.[9]
References
[edit]- 1 2 3 GRCh38: Ensembl release 89: ENSG00000089123 – Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000039033 – Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ Hsieh JJ, Cheng EH, Korsmeyer SJ (November 2003). "Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression". Cell. 115 (3): 293–303. doi:10.1016/S0092-8674(03)00816-X. PMID 14636557. S2CID 18952302.
- 1 2 "Entrez Gene: TASP1 taspase, threonine aspartase, 1".
- ↑ Oyama T, Sasagawa S, Takeda S, Hess RA, Lieberman PM, Cheng EH, et al. (October 2013). "Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs". Developmental Cell. 27 (2): 188–200. doi:10.1016/j.devcel.2013.09.025. PMC 3947863. PMID 24176642.
- ↑ Chen DY, Liu H, Takeda S, Tu HC, Sasagawa S, Van Tine BA, et al. (July 2010). "Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis". Cancer Research. 70 (13): 5358–5367. doi:10.1158/0008-5472.CAN-10-0027. PMC 2909739. PMID 20516119.
- ↑ Suleiman J, Mundt M, Sampath S, El-Hattab AW (July 2018). "TASP1 is deleted in an infant with developmental delay, microcephaly, distinctive facial features, and multiple congenital anomalies". Clinical Genetics. 94 (1): 170–173. doi:10.1111/cge.13258. PMID 29633245.
Further reading
[edit]- Zhou H, Spicuglia S, Hsieh JJ, Mitsiou DJ, Høiby T, Veenstra GJ, et al. (April 2006). "Uncleaved TFIIA is a substrate for taspase 1 and active in transcription". Molecular and Cellular Biology. 26 (7): 2728–2735. doi:10.1128/MCB.26.7.2728-2735.2006. PMC 1430320. PMID 16537915.
- Khan JA, Dunn BM, Tong L (2006). "Crystal structure of human Taspase1, a crucial protease regulating the function of MLL". Structure. 13 (10). London: 1443–1452. doi:10.1016/j.str.2005.07.006. PMID 16216576.
- Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ (January 2003). "Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization". Molecular and Cellular Biology. 23 (1): 186–194. doi:10.1128/MCB.23.1.186-194.2003. PMC 140678. PMID 12482972.